Finding an option with presbyopia-correcting IOLs
Cataract surgeons appear to have growing confidence using presbyopia-correcting IOLs in patients with a history of keratorefractive surgery.
This article was reviewed by Arthur B. Cummings, MD
Though a history of keratorefractive surgery has generally been considered a contraindication to implantation of a presbyopia-correcting
According to Arthur B. Cummings, MD, consultant eye surgeon and medical director, Wellington Eye Clinic, Dublin, Ireland, patients who have previously undergone keratorefractive procedures and enjoyed the benefits of good vision demand similar results after
“But
Related: Light-adjustable IOL technology creates novel treatment window
Dr. Cummings sought to identify current practices for using presbyopia-correcting
Additional data collected in the survey indicated that greater use of presbyopia-correcting
“When considering whether or not a patient is a good candidate for a presbyopia-correcting
Related: Presbyopia-correcting IOLs: Expanding, improving last frontier
Among the surgeons who were not using presbyopia-correcting
According to Dr. Cummings, opinions were mixed on whether better outcomes could be achieved in patients who had undergone keratorefractive surgery for myopia versus hyperopia.
The level of correction was considered when deciding to use a presbyopia-correcting
Related:
IOL preferences
Given a list of IOL design types, the surgeons’ responses indicated that their most satisfactory results overall were achieved using the pinhole optic IOL (IC-8, AcuFocus) followed by trifocal lenses.
“The survey responses indicated that good results could be achieved with all presbyopia-correcting IOL designs,” Dr. Cummings noted.
Corresponding with the preference for the pinhole optic
“The IC-8 accounted for more than half of the presbyopia-correcting lenses implanted in eyes with irregular
Read more by Cheryl Guttman Krader, BS, Pharm
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Articles
- Q&A: Robyn Guymer highlights risk factors of intermediate AMD
September 20th 2025
- iVeena secures $2 million NEI SBIR grant to advance pediatric myopia therapy
September 20th 2025
- Part 6: What if? Curing any eye disease with the snap of your finger
September 19th 2025